Prognostic Value Analysis of Mutational and Clinicopathological Factors in Non-Small Cell Lung Cancer

Chenguang Li1,2,3, *, Ligang Hao1,2,3,*, Yue Li1,2,3, Shengguang Wang1,2,3, Hui Chen1,2,3, Lianmin Zhang1,2,3, Bin Ke2,4, Yuesong Yin1,2,3, Haijin Suo1,2,3,5, Bingsheng Sun1,2,3, Bin Zhang1,2,3, Changli Wang1,2,3,*

1 Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China, 2 Key Laboratory of Cancer Prevention and Therapy, Tianjin, China, 3 Tianjin Lung Cancer Center, Tianjin, China, 4 Department of Gastric Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, 5 Department of Surgery, Tianjin Beichen Hospital, Tianjin, China

Abstract

Introduction: Targeting activating oncogenic driver mutations in lung adenocarcinoma has led to prolonged survival in patients harboring these specific genetic alterations. The prognostic value of these mutations has not yet been elucidated. The prevalence of recently uncovered non-coding somatic mutation in promoter region of TERT gene is also to be validated in lung cancer. The purpose of this study is to show the prevalence, association with clinical-pathological features and prognostic value of these factors.

Methods: In a cohort of patients with non-small cell lung cancer (NSCLC) (n = 174, including 107 lung adenocarcinoma and 67 lung squamous cell carcinoma), EGFR, KRAS, HER2 and BRAF were directly sequenced in lung adenocarcinoma, ALK fusions were screened using FISH (Fluorescence in situ Hybridization). TERT promoter region was sequenced in all of the 174 NSCLC samples. Associations of these somatic mutations and clinicopathological features, as well as prognostic factors were evaluated.

Results: EGFR, KRAS, HER2, BRAF mutation and ALK fusion were mutated in 25.2%, 6.5%, 1.9%, 0.9% and 3.7% of lung adenocarcinomas. No TERT promoter mutation was validated by reverse-sided sequencing. Lung adenocarcinoma with EGFR and KRAS mutations showed no significant difference in Disease-free Survival (DFS) and Overall Survival (OS). Cox Multi-variate analysis revealed that only N stage and HER2 mutation were independent predictors of worse overall survival (HR = 1.653, 95% CI 1.219–2.241, P = 0.001; HR = 12.344, 95% CI 2.615–58.275, P = 0.002).

Conclusions: We have further confirmed that TERT promoter mutation may only exist in a very small fraction of NSCLCs. These results indicate that dividing lung adenocarcinoma into molecular subtypes according to oncogenic driver mutations doesn’t predict survival difference of the disease.

Introduction

Lung cancer is one of the most devastating diseases and the leading cause of cancer-related deaths worldwide [1]. Non-small cell lung cancer (NSCLC), which accounts for about 85% of lung cancer cases, is further divided to histological subtypes of adenocarcinoma (ADC), squamous cell carcinoma (SCC) and large cell carcinoma. Adenocarcinoma has become the most common lung cancer subtype [2]. The 5-year survival rate of NSCLC remains low as 15–16%, despite improvement of treatment in the past decades [1,3]. Better understanding of the NSCLC tumorigenesis and factors associated with prognosis is needed.

Uncovering of activating mutations in tyrosine kinase domain of EGFR has led to developing and wide use of gefetinib and erlotinib, which has proven to be effective in the treatment for part
of EGFR mutated lung adenocarcinomas [2,4]. According to specific oncogenic driver mutations, lung adenocarcinoma is divided to molecular subtypes such as EGFR, KRAS, ALK, HER2, BRAF and so on [5,6]. Most of these driver genes have specific targeted drugs in use or clinical trials. Compared to adenocarcinoma, knowledge on genetic alterations of lung squamous cell carcinoma is limited. Frequent mutation, amplification or loss of FGFR1, PTEN, PIK3CA, NFE2L2, NRF have been identified in comprehensive genomic study in lung squamous cell carcinoma [7]. Because the largely undefined mutational spectrum and low frequencies of these genes, targeted therapies in lung squamous cell carcinoma is lagging behind and constricted to clinical trials.

Recently, human cancer genome sequencing studies have revealed somatic mutations in the core promoter of human telomerase reverse transcriptase (hTERT). Gene, which codes the catalytic subunit of telomerase [8–10]. Either C228T or C250T of hTERT promoter mutations elevated transcriptional activity of hTERT gene in the luciferase reporter assays [8]. The tumor types with frequent hTERT promoter mutations included Melanoma (71%), Glioma (51%), Myxoid liposarcoma (79%), Urothelial carcinoma of bladder (66%) [8,9]. Evidences in above studies suggested that hTERT promoter mutations potentially act as a driver gene in melanoma. However, the prevalence of hTERT promoter mutation in lung cancer clinical samples is absent in these studies. It’s necessary to show the prevalence of hTERT promoter mutation in NSCLC samples as lung cancer shares driver mutated genes with melanoma, such as BRAF and NRAS [8,9,11].

In this study, we aimed to show the comprehensive molecular and clinicopathological features in NSCLC, as well as the prognostic value of these characteristics.

Table 1. Demographics and clinicopathologic features of 174 patients with NSCLC.

| Variables                        | No. of patients (%) |
|----------------------------------|---------------------|
| Age                              |                     |
| ≤50                              | 37 (21.3)           |
| 51–60                            | 69 (39.6)           |
| 61–70                            | 49 (28.2)           |
| >70                              | 19 (10.9)           |
| Mean ± SD (range)                | 58.17 ± 9.44        |
| Histologic subtype               |                     |
| Adenocarcinoma                   | 107 (61.5)          |
| Squamous cell carcinoma          | 67 (38.5)           |
| Smoking status                   |                     |
| Smoker                           | 109 (62.6)          |
| Non-smoker                       | 65 (37.4)           |
| Stage                            |                     |
| IA                               | 24 (13.8)           |
| IB                               | 33 (18.9)           |
| IIA                              | 30 (17.2)           |
| IIB                              | 16 (9.2)            |
| IIIA                             | 68 (39.1)           |
| IIIb                             | 1 (0.5)             |
| NA                               | 2 (1.1)             |
| Total                            | 174                 |

SD, standard deviation; NA, not applicable.

doi:10.1371/journal.pone.0107276.t001

Figure 1. Pie chart of EGFR, KRAS, HER2 and BRAF mutation spectrum from 107 lung adenocarcinomas. The mutation rates of EGFR, KRAS, HER2 and BRAF were 25.2, 5.6, 1.9 and 0.9%, respectively. doi:10.1371/journal.pone.0107276.g001
Methods

Patients and tissues

Primary tumor samples were obtained from 174 patients who underwent potentially curative pulmonary resection at the Tianjin Medical University Cancer Hospital from Jan 2004 through Jan 2008. This study was approved by the Institutional Review Board of Tianjin Medical University Cancer Institute and Hospital. All participants gave written informed consent. Patients were enrolled in this specific study based upon the following criteria: they had a pathologic diagnosis of lung adenocarcinoma or squamous cell carcinoma, their tumor sample contained a minimum of 50% tumor cells as determined by study pathologists, they did not receive neoadjuvant chemotherapy, and they had sufficient tissue for molecular analysis. Clinicopathological features and prognosis information were collected.

DNA isolation and mutational analysis

Genomic DNA were isolated from Formalin-Fixed Paraffin-Embedded (FFPE) samples according to standard protocols (TIANquick FFPE DNA Kit, Tiangen Inc, China). EGFR (exons 18–22), HER2 (exon 20), KRAS (exons 2 to 3), BRAF (exon 15) and TERT promoter region were PCR amplified using DNA and directly sequenced. Multiplex PCR analysis was done with rTaq DNA polymerase (Toyobo, Osaka, Japan). Primers used in these experiments are listed in Table S1. ALK fusions were screened using FISH with FFPE slides.

Statistical analysis

Associations between mutations and clinical and biological characteristics were analyzed by \( \chi^2 \) or Fisher’s exact test. Survival curves were drawn by the Kaplan–Meier method. The Cox proportional hazards regression (forward likelihood ratio model) was used for multivariate survival analyses. All data were analyzed...
using the Statistical Package for the Social Sciences Version 16.0 Software (SPSS Inc., Chicago, IL). The two-sided significance level was set at $P<0.05$.

Results

Patient Characteristics

One hundred and seven lung ADC and 67 SCC patients were enrolled in this study, including 105 men and 69 women (average 58 years; range, 39–77 years). There were 109 smokers and 65 non-smokers, accounting for 63% and 37%, respectively. The number of patients in stages I-III was 57, 46, and 69, respectively. Two samples were with undefined stage. The detailed information is listed in Table 1.

EGFR, KRAS, HER2 and BRAF Mutation Status and ALK fusions

Of the 107 lung adenocarcinoma samples, 25.2% (27/107) of tumors were found to harbor EGFR kinase domain mutations. Among these, 17 were deletions in exon 19 and 6 were L858R missense changes. Other alterations included 1 exon 20 insertion, 1 exon 18 R705K mutation. Six samples (5.6%) had a KRAS mutation, including five G12V mutations and an I36M missense mutation. Two samples harbored HER2 exon 20 mutation, including a 776 to 779 YVMA insertion and a S789P mutation. Only one BRAF L588F missense mutation was identified in these tumor samples (Figure 1). ALK fusions were detected in 4 (3.7%) samples. Because mutations of EGFR, KRAS, HER2, BRAF, as well as ALK fusions have been well established to be existed in lung adenocarcinoma [5,12–14], these mutation and fusion genes that ‘drives’ lung adenocarcinoma were not screened in lung squamous cell carcinoma.

Survival Analysis

By univariate analysis, advanced clinical staging ($P=0.018$), lymphnode metastasis ($P<0.001$), $\geq 2$ station of metastatic lymphnode ($P<0.001$), received adjuvant chemotherapy ($P=0.004$) were associated disease relapse (Table 2). EGFR and KRAS mutation status were not associated with relapse-free survival ($P=0.600$) or overall survival in lung adenocarcinoma ($P=0.873$) (Figure 2). Cox multivariate forward stepwise analysis (adjusting for age, gender, smoking history, clinical stage, histologic subtypes and mutational status) revealed that only lymphnode stage (N stage) and HER2 mutation was independent predictors of poorer overall survival ($HR=1.653, 95\% CI 1.219–2.241; P=0.001$; $HR=12.344, 95\% CI 2.615–58.275; P=0.002$). Detailed mutational and survival information is listed in Table S2.

Discussion

NSCLC is a heterogeneous disease, outcome differs even in patients with identical clinicopathologic features. Identification of oncogenic driver mutations in lung adenocarcinoma has greatly promoted clinical use and development of targeted drugs [5,6,15,16]. Though EGFR and KRAS mutations have been established as predictive and prognostic markers for patients who receive EGFR-TKIs [4,17,18], results on the prognostic value of these alterations at genomic level in patients who didn’t receive EGFR-TKIs were rarely reported.

Table 2. Association between clinical and molecular factors and disease relapse.

| Factors                        | Relapse | $P$  |
|-------------------------------|---------|------|
| Clinical Stage                |         |      |
| I                             |         |      |
| II                            | I       |      |
| III                           | II      |      |
| EGFR status                   |         |      |
| Mutated                       | I       |      |
| Wildtype                      | II      |      |
| KRAS status                   |         |      |
| Mutated                       | III     |      |
| Wildtype                      |         |      |
| Lymphnode metastasis          |         |      |
| Positive                      | I       |      |
| Negative                      | II      |      |
| No. of metastatic lymphnode station | III     |      |
| <2                            | I       |      |
| $\geq 2$                      | II      |      |
| Adjuvant Chemotherapy         |         |      |
| Received                      | III     |      |
| Not-received                  |         |      |

5’ non-coding region mutations of TERT gene in NSCLC

Neither C228T nor C250T mutations was validated in the 174 NSCLC samples after reverse sequencing. These results indicated that TERT promoter mutation may only exist in a very small fraction of primary NSCLC samples.
We have screened the prevalence of known driver mutations of EGFR, KRAS, HER2, BRAF and ALK in a cohort of 107 lung adenocarcinoma sample with complete prognostic information. The EGFR mutation, KRAS mutation and EGFR/KRAS wild type groups showed no significant difference in both relapse-free survival and overall survival in the present study. All the patients enrolled in this study didn’t receive small molecular drugs targeting EGFR. Our results suggest that specific driver mutation of EGFR or KRAS gene doesn’t predict survival advantage or disadvantage when these patients didn’t receive specific target therapies. In the multivariate analysis, HER2 mutation was identified as independent predictor of unfavorable prognosis. Because only two samples harbored HER2 mutation, further study with larger number of samples are needed to confirm this result. Based on these facts, we conclude that to divide lung adenocarcinoma into molecular subtypes only predicts therapy response but not survival benefit in patients who didn’t receive these drugs.

The emerging of somatic mutations of hTERT gene 5’ promoter region in melanoma has provided another promising candidate driver gene for lung cancer. Several studies have identified frequent hTERT 5’ promoter mutations in melanoma [8,10], gliomas, as well as from relatively low rates of self renewal tissues like liposarcomas, hepatocellular carcinomas, urothelial carcinomas, squamous cell carcinomas of the tongue and medulloblastomas [9,19]. We screened the hTERT 5’ promoter region in 174 NSCLC FFPE samples to explore the mutation rate and potential prognostic value. We identified only three C250T mutations from the 174 samples, but none of these were validated by reverse sequencing, which could be possibly caused by DNA damage in the process of formalin fixing and paraffin embedding. These results confirmed that hTERT 5’ promoter mutations may only exist in a very small fraction of NSCLC cases.

The limitation of the present study should be discussed. In order to explore the prognostic significance, we used FFPE samples which have complete survival information. However, the sensitivity of sequencing results is affected by the relatively low quality of FFPE samples, in which DNA is degraded and artificially mutated. The mutation rate of well known driver genes is lower than previous studies using high quality snap-frozen samples [20,21], and the artificial mutations appeared in hTERT 5’ promoter region. Though consecutive samples with complete survival data are not always available, our study provided the mutation spectrum and prognostic association of these genetic alterations with available sample and techniques.

In conclusion, our work illustrated the mutation spectrum of EGFR, KRAS, HER2, BRAF and ALK in lung adenocarcinoma, as well as confirmed that hTERT 5’ promoter region mutation rarely occurred in NSCLC samples. We also confirmed that these driver mutations lack prognostic value in lung adenocarcinoma patients who didn’t receive EGFR TKI treatment, and subtypes divided by these oncogenic driver mutations don’t predict significant survival difference.

Supporting Information

Table S1 List of primers used for polymerase chain reaction amplification of the EGFR, KRAS, HER2 and BRAF gene.

Table S2 Mutational and survival information of 174 NSCLC patients. Sex, 1 male, 2 female; Smoking, 0 non-smoker, 1 smoker; path, pathology; WT, wild-type; DEL, deletion; INS, insertion; NEG, negative; POS, positive.

Author Contributions

Conceived and designed the experiments: CL CW. Performed the experiments: CL LH BZ YL SW HC LZ BK. Analyzed the data: CL LH BZ YL SW HC LZ BK. Contributed reagents/materials/analysis tools: BK HS. Contributed to the writing of the manuscript: CL CW LH.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90.
2. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359: 1367–1380.
3. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64: 9–29.
4. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21: 2237–2246.
5. Pao W, Hutchinson KE (2012) Chipping away at the lung cancer genome. Nat Med 18: 349–351.
6. Li C, Fang R, Sun Y, Han X, Li F, et al. (2011) Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One 6: e29204.
7. Cancer Genome Atlas Research N (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489: 519–525.
8. Huang FW, Hsieh E, Xie MJ, Kryukov GV, Chin L, et al. (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339: 957–959.
9. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, et al. (2013) TERT promoter mutations in melanoma. Science 339: 957–959.
10. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, et al. (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339: 957–959.
11. Bucher AD, Sydloves E, Jakob JA, Bassett RL, Jr., Curry JL, et al. (2013) Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer 119: 3821–3829.